Rocket Lab is no longer just a launch provider. The company’s $8 billion acquisition of Iridium Communications marks a decisive pivot toward becoming a fully integrated space operator — one that owns not only rockets but also a constellation of satellites, exclusive spectrum rights, and a base of 2.5 million paying customers spanning government, military, and commercial sectors. The stock, trading at €89.40, has surged more than 207% over the past twelve months, reflecting investor enthusiasm for the strategic shift.
The purchase price of $54 per Iridium share represents a 24.1% premium over the unaffected price. Iridium shareholders will receive half in cash — $27 per share — and half in Rocket Lab stock, with an exchange ratio collar set between $67.50 and $112.50 to guard against volatility. Both boards have unanimously approved the transaction, which is expected to close by mid-2027, pending regulatory green lights. Rocket Lab CEO Peter Beck described the deal as a “pivotal moment for the space industry” and a shortcut into the market for space applications, a sector where building comparable infrastructure from scratch would take years.
To finance the cash portion and assume roughly $2.1 billion in existing Iridium debt, Rocket Lab has secured a $3.6 billion bridge facility arranged by Deutsche Bank and Wells Fargo with a 364-day term. This allows the company to move quickly while it arranges permanent financing. For Iridium, those figures are substantial: the satellite operator generated $871.7 million in revenue in 2025, with an operating EBITDA of $495 million — a healthy 57% margin. Analysts at Bank of America estimate the combination will roughly double Rocket Lab’s revenue and push the merged entity into EBITDA-positive territory from day one.
Should investors sell immediately? Or is it worth buying Rocket Lab?
Rocket Lab enters the deal on strong operational footing. First-quarter revenue rose 63% year over year to roughly $200 million, and the company’s backlog stood at more than $2.2 billion even before the Iridium announcement. During the first three months of the year, Rocket Lab signed 31 new launch contracts. Lucrative defense work has also flowed in: the US Department of Defense booked hypersonic test flights worth $190 million, and Anduril Industries placed orders for an additional $30 million in testing services. The core launch business, in short, is firing on all cylinders.
Wall Street has responded with a flurry of target upgrades. Roth MKM raised its price objective from $100 to $130, while Citizens lifted its from $95 to $130. Needham and Craig-Hallum both set targets at $120, up from $98 in Craig-Hallum’s case. BofA Securities moved its target from $105 to $115. All five houses maintain buy ratings. Technically, the stock currently trades about 36% above its 200-day moving average of €65.65, though it has slipped roughly 15% over the past month. The relative strength index sits at a neutral 49, and annualised volatility stands at 108% — a reminder of how sharply the shares can move on news.
The real test lies ahead. Rocket Lab is still developing its Neutron medium-lift rocket, with the first flight targeted for the fourth quarter of 2026. If that debut stays on schedule, the company will have a second growth driver in the air well before the Iridium deal closes. Neutron, priced at up to $55 million per launch, directly targets the market occupied by SpaceX’s Falcon 9 and promises to multiply revenue per mission. For now, the Iridium acquisition provides an immediate shortcut to scale — and the market is leaning in.
Ad
Rocket Lab Stock: Buy or Sell?! New Rocket Lab Analysis from July 1 delivers the answer:
The latest Rocket Lab figures speak for themselves: Urgent action needed for Rocket Lab investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 1.
Rocket Lab: Buy or sell? Read more here...
